Asset Details
Do you wish to reserve the book?
3138 Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosis
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
3138 Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosis
Do you wish to request the book?
3138 Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosis
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
3138 Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosis
2024
Overview
Background/ObjectivesCladribine reduces the frequency of relapses by 57% and disability worsening by 33% compared to placebo in relapsing-remitting multiple sclerosis (RRMS). No head-to-head comparisons of cladribine to other potent immunotherapies are available.MethodsPatients with RRMS who were treated with cladribine, fingolimod, natalizumab, ocrelizumab or alemtuzumab from 01/2018 were identified in the global MSBase cohort study and 2 UK centres. Included patients were followed for >=6 months and had a minimum of 3 disability assessments. Patients were matched using propensity score. Four pairwise analyses compared annualised relapse rates (ARR), and disability outcomes. All subsequent events were analysed, regardless of changes in treatment status.ResultsThe eligible cohorts consisted of 853(fingolimod), 464(natalizumab), 1131(ocrelizumab), 123(alemtuzumab), or 493(cladribine) patients. Cladribine was associated with a lower ARR than fingolimod (ARR 0.07 vs 0.12,p=0.006), and a higher ARR than natalizumab (0.10 vs 0.06,p=0.03), ocrelizumab (0.09 vs 0.05,p=0.008), and alemtuzumab (0.17 vs 0.04,p<0.001). Compared to cladribine, the risk of disability worsening did not differ in patients treated with fingolimod (HR1.08, 95%CI 0.47–2.47) or alemtuzumab (0.73, 0.26–2.07), but was lower for patients treated with natalizumab (0.35, 0.13–0.94) and ocrelizumab (0.45, 0.26–0.78).ConclusionCladribine is an effective therapy, associated with low absolute ARR. While cladribine effectiveness on relapses is superior to fingolimod, alemtuzumab is superior to cladribine in reducing relapses. Natalizumab and ocrelizumab are superior to cladribine in reducing both relapses and disability accrual. Cladribine can thus be viewed as a step-up in effectiveness from fingolimod, but less effective than the most potent intravenous MS therapies.
Publisher
BMJ Publishing Group Ltd,BMJ Publishing Group LTD,BMJ Publishing Group
Subject
